Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets falls 20.4% from a year ago
Other current assets stood at $1.09M at the end of Q1 FY2026, down 20.4% from a year earlier and down 7.0% from the prior quarter. Over 3 fiscal years it compounded at +94.6% a year.
Context
- Other current assets amounted to 1.7% of total assets at the end of Q1 FY2026, down 3.2 pp from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -20.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.17M USD
- Year-over-year change
- +24.7%
- 4-year CAGR
- +74.6%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.17M | +24.7% |
| FY2024 | 2024-12-31 | 939K | +188.9% |
| FY2023 | 2023-12-31 | 325K | +104.4% |
| FY2022 | 2022-12-31 | 159K | +26.2% |
| FY2021 | 2021-12-31 | 126K | — |
Other Current Assets vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -20.4% is the 5th highest of 8, against a peer median of -12.4%.
- Other current assets amounts to 1.7% of total assets for UNCY, versus a peer median of 0.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.99M USD | +725.4% | — | 2.8% | |
| Mar 2026 | $2.23M USD | -28.3% | -27.3% | 2.3% | |
| Mar 2026 | $1.63M USD | +83.2% | -22.3% | 3.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $1.48M USD | -12.4% | -24.6% | 1.4% |
| Mar 2026 | $1.38M USD | — | — | 0.6% | |
| Mar 2026 | $1.09M USD | -20.4% | +94.6% | 1.7% | |
| Mar 2026 | $1.06M USD | -54.7% | -30.6% | 0.6% | |
CBUSCibus, Inc. | Mar 2026 | $941K USD | -30.1% | +27.0% | 0.3% |
| Mar 2026 | $614K USD | +63.7% | -30.7% | 0.3% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$3 CAD | — | — | 0.0% |
| Peer median (excluding UNCY) | — | -12.4% | -26.0% | 0.6% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.